Mustafa MAKAV, Gözde ATİLA USLU, Ömür ÖZTÜRK, Yasemen ADALI, Ali BİLGE, Murat TÜYSÜZ, Ramazan TISKAOĞLU, Hüseyin Avni EROĞLU

Deneysel Olarak Gut Oluşturulmuş Ratlarda Ozon Terapinin Etkisi

Bu çalışmada deneysel olarak Gut artriti oluşturulmuş rat ekleminde ozon tedavisinin etkisi araştırıldı. Yirmi adet albino cinsi erişkin erkek rat 4 gruba bölünerek: 1. Gruba (Kontrol) herhangi bir ilaç verilmeden takip edildi, 2. Gruba (Gut kontrol) deneysel Gut artriti oluşturulmak üzere tek doz 0.2 mL (10 mg) monosodyum ürat (MSU) 1. metatarsofalengeal ekleme enjekte edildi, 3. Gruba (Gut + Ozon) deneysel Gut oluşturulmak üzere tek doz 0.2 mL (10 mg) monosodyum ürat (MSU) 1. metatarsofalengeal ekleme intraartiküler olarak enjekte edildi ve arkasından ratlara 3 hafta süreyle günde tek doz 1 mL (10 µg/mL) intraperitoneal ozon terapi verildi, 4. Gruba ise (Ozon kontrol) Gut oluşturulmaksızın 3 hafta günde tek doz 1 mL (10 µg/mL) intraperitoneal ozon terapi uygulandı. Sonuçlar patolojik olarak kayıt altına alındı ve gruplar arası istatistik olarak karşılaştırıldı. Sonuç olarak 3. Gruptaki (Gut + Ozon) inflamasyon düzeyindeki düşüklük 2. Gruba göre istatistikse olarak anlamlı kabul edildi. Ozon tedavisinin Gut oluşturulan eklemde akut inflamasyonu azalttığı gösterilse de kronik olan proliferasyon sürecine etkisi görülmedi.

The Investigation of the Effect of Ozone Therapy on Gout in Experimental Rat Models

The effect of ozone treatment in experimental rat gout arthritis was investigated. Twenty adult albino male rats were divided into 4 groups:Group 1 (Control) was followed without any medication, Group 2 (Gout control) was injected with a single dose of 0.2 mL (10 mg) monosodiumurate (MSU) intraarticulary to 1st metatarsophalangeal joint to create experimental Gouty arthritis. Group 3 (Gout + Ozone) was injectedintraarticulary to 1st metatarsophalangeal joint with a single dose of 0.2 mL (10 mg) MSU to generate experimental gout, followed by ozonetherapy to the rats a single dose of 1 mL (10 µg/mL) intraperitoneally daily for 3 weeks. The Group 4 (Ozone control) ozone therapy wasgiven a single dose of 1 mL (10 µg/mL) intraperitoneally daily for 3 weeks without gout formation. The results were recorded and comparedstatistically between the groups. In conclusion, the low level of inflammation in the third group (Gout + Ozone) was considered statisticallysignificant as compared to the second group. With Ozone treatment the gout joint has been shown to have reduced acute inflammation, ithas not been affected by the chronic proliferation process.

PDF

___

1. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T: American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 64, 1447-1461, 2012. DOI: 10.1002/acr.21773
2. Ahern M, Reid C, Gordon T, McCredle M, Brooks PM, Jones M: Does colchicine work? The results of the first controlled study in acute gout. Intern Med J, 17 (3): 301-304, 1987. DOI: 10.1111/j.1445-5994.1987. tb01232.x
3. Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R: Prophylactic colchicine therapy of intercritical gout. A placebo‐controlled study of probenecid‐treated patients. Arthritis Rheu, 17 (5): 609-614, 1974. DOI: 10.1002/art.1780170517
4. Zhu Y, Pandya BJ, Choi HK: Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheu, 63 (10): 3136-3141, 2011. DOI: 10.1002/art.30520
5.Martillo MA, Nazzal L, Crittenden DB: The crystallization of monosodium urate. Curr Rheumatol Rep, 16:400, 2014. DOI: 10.1007/s11926-013-0400-9
6. Parekh BB, Vasant SR, Tank KP, Raut A, Vaidya ADB, Joshi MJ: In vitro growth and inhibition studies of monosodium urate monohydrate crystals by different herbal extracts. Am J infect Dis, 5(3): 225-230, 2009. DOI: 10.3844/ajidsp.2009.225.230
7. Richette P, Bardin T: Gout. Lancet, 375 (9711): 318-328, 2010. DOI: 10.1016/s0140-6736(09)60883-7
8. Cronstein BN, Terkeltaub R: The inflammatory process of gout and its treatment. Arthritis Res Ther, 8 (Suppl. 1): S3, 2006. DOI: 10.1186/ar1908
9. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J: Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature, 440, 237-241, 2006. DOI: 10.1038/nature04516
10. Pouliot M, James MJ, McColl SR, Naccache PH, Cleland LG: Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood, 91 (5): 1769-1776, 1998.
11. Punzi L, Scanu A, Ramonda R, Oliviero F: Gout as autoinflammatory disease: New mechanisms for more appropriated treatment targets. Autoimmun Rev, 12 (1): 66-71, 2012. DOI: 10.1016/j.autrev.2012.07.024
12. Bocci VA: Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res, 37 (4): 425-435, 2006. DOI: 10.1016/j.arcmed.2005.08.006
13. Tapia SA, Grigorio MS: Ozone therapy and its scientific foundations. Биорадикалы и антиоксиданты, 1 (1): 10-33, 2014.
14. Bocci V: Ozone: A new medical drug. 19-29. Springer, Netherlands. 2005. DOI: 10.1007/1-4020-3140-8
15. do Prado Vendruscolo C, Moreira JJ, Seidel SRT, Fülber J, Neuenschwander HM, Bonagura G, Agreste FR, Baccarin RYA: Effects of medical ozone upon healthy equine joints: Clinical and laboratorial aspects. PloS One 13 (5):e0197736, 2018. DOI: 10.1371/journal. pone.0197736
16. Terkeltaub R: Update on gout: New therapeutic strategies and options. Nat Rev Rheumatol, 6 (1): 30-38, 2010. DOI: 10.1038/nrrheum. 2009.236
17. Camelia C, Madalina I, Tatiana M, Marilena P, Oana A: The role of ozone therapy in maintaining the articular function and in relieving the pain for patients with knee osteoarthritis. Arsm, 20 (1): 25-29, 2014. DOI: 10.2478/arsm-2014-0005
18. Fernandez-Cuadros ME, Perez-Moro OS, Albaladejo-Florin MJ, Algarra-Lopez R: Intra articular ozone reduces serum uric acid and ımproves pain, function and quality of life in knee osteoarthritis patients: A before-and-after study. Middle East J Rehabil Health Stud, 5 (3): e68599, 2018. DOI: 10.5812/mejrh.68599
19. LI LY, NI JX: Efficacy and safety of ozonated autohemotherapy in patients with hyperuricemia and gout: A phase I pilot study. Exp Ther Med, 8 (5): 1423-1427, 2014. DOI: 10.3892/etm.2014.1951
20. Bilge A, Ozturk O, Adali Y, Ustebay S: Could ozone treatment be a promising alternative for osteomyelitis? An experimental study. Acta Ortop Bras, 26 (1): 67-71, 2018. DOI: 10.1590/1413-785220182601179926